SGR-3515 (Wee1 inhibitor)

February 25, 2026: Schrödinger, Inc. (NASDAQ: SDGR) reported 4Q and full-year 2025 results and provided 2026 outlook/2028 objectives, alongside R&D and partnering updates relevant to its drug discovery pipeline and collaborators’ programs.

Schrödinger proprietary programs:

• SGR-1505 (MALT-1 inhibitor; relapsed/refractory B-cell malignancies): completing Phase 1 clinical packages; exploring strategic partnerships.
• SGR-3515 (Wee1/Myt1 inhibitor; solid tumors): completing Phase 1 clinical packages; expects to present initial data in 2Q 2026; exploring strategic partnerships.

Collaborator/co-founded company catalysts noted:

• Structure Therapeutics: aleniglipron (oral GLP-1 receptor agonist; obesity) reported positive topline Phase 2B data (December); plans to initiate Phase 3 in mid-2026. ACCG-2671 (oral amylin receptor agonist; obesity) initiated first-in-human Phase 1 (December).
• Ajax Therapeutics: AJ1-11095 (type II JAK2 inhibitor; Phase 1 in relapsed/refractory myelofibrosis) presented preclinical data at ASH (December) and received FDA orphan drug designation for myelofibrosis (December).
• Takeda: zasocitinib (TYK2 inhibitor; moderate-to-severe plaque psoriasis) reported positive topline Phase 3 results (December) and intends to file an FDA NDA in 2026.